Tech Company Financing Transactions
Navrogen Funding Round
Ben Franklin Technology Partners and private investors invested in a $3.2 million funding round for Navrogen. The round closed on 9/19/2019.
Transaction Overview
Company Name
Announced On
9/19/2019
Transaction Type
Debt
Amount
$3,200,000
Round
Undisclosed
Investors
Ben Franklin Technology Partners (Lead Investor)
Proceeds Purpose
The use of proceeds, in addition to grant funding, will be used to expand Navrogen's HIO-factor library and support preclinical development activities around its therapeutic pipeline.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
5600 City Ave. Lower Merion Township
Philadelphia, PA 19131
USA
Philadelphia, PA 19131
USA
Phone
Website
Email Address
Not Recorded
Overview
NavrogenTM Inc. is a biotechnology company focused on the discovery of tumor produced HIO-factors that are associated with cancer prognosis and therapeutic response of immune-mediated anti-cancer therapies.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Nicholas Nicolaides
Chief Scientific Officer
Luigi Grasso
VP - Finance
Steven Kyriakos
VP - R & D
Brad Kline
Browse more venture capital transactions:
Prev: 9/19/2019: Indus.ai venture capital transaction
Next: 9/19/2019: WanderJaunt venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to document all VC transactions involving tech companies. All VC database entries reported here are derived from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs